1. Home
  2. AGEN vs SRL Comparison

AGEN vs SRL Comparison

Compare AGEN & SRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGEN
  • SRL
  • Stock Information
  • Founded
  • AGEN 1994
  • SRL 2017
  • Country
  • AGEN United States
  • SRL China
  • Employees
  • AGEN N/A
  • SRL N/A
  • Industry
  • AGEN Biotechnology: Biological Products (No Diagnostic Substances)
  • SRL Professional Services
  • Sector
  • AGEN Health Care
  • SRL Consumer Discretionary
  • Exchange
  • AGEN Nasdaq
  • SRL Nasdaq
  • Market Cap
  • AGEN 87.7M
  • SRL 89.5M
  • IPO Year
  • AGEN 2000
  • SRL N/A
  • Fundamental
  • Price
  • AGEN $5.29
  • SRL $5.76
  • Analyst Decision
  • AGEN Strong Buy
  • SRL
  • Analyst Count
  • AGEN 3
  • SRL 0
  • Target Price
  • AGEN $16.33
  • SRL N/A
  • AVG Volume (30 Days)
  • AGEN 1.2M
  • SRL 4.4K
  • Earning Date
  • AGEN 08-11-2025
  • SRL 08-12-2025
  • Dividend Yield
  • AGEN N/A
  • SRL 18.09%
  • EPS Growth
  • AGEN N/A
  • SRL N/A
  • EPS
  • AGEN N/A
  • SRL N/A
  • Revenue
  • AGEN $99,524,000.00
  • SRL $24,535,042.00
  • Revenue This Year
  • AGEN $25.31
  • SRL N/A
  • Revenue Next Year
  • AGEN N/A
  • SRL N/A
  • P/E Ratio
  • AGEN N/A
  • SRL N/A
  • Revenue Growth
  • AGEN N/A
  • SRL N/A
  • 52 Week Low
  • AGEN $1.38
  • SRL $5.52
  • 52 Week High
  • AGEN $7.34
  • SRL $9.99
  • Technical
  • Relative Strength Index (RSI)
  • AGEN 44.92
  • SRL 38.77
  • Support Level
  • AGEN $5.34
  • SRL $5.51
  • Resistance Level
  • AGEN $6.58
  • SRL $6.21
  • Average True Range (ATR)
  • AGEN 0.44
  • SRL 0.25
  • MACD
  • AGEN -0.16
  • SRL -0.02
  • Stochastic Oscillator
  • AGEN 10.69
  • SRL 30.12

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

About SRL Scully Royalty Ltd.

Scully Royalty Ltd is a royalty-based company that maximizes earnings upon its iron ore royalty interest. The company's business segments include Royalty, which includes an interest in an iron ore mine; Industrial, which includes projects in resources and services; Merchant Banking, which comprises regulated merchant banking activities; and others. The majority of the revenue is generated from the Royalty segment. The company's geographical segments include Canada, Africa, America, Asia, and Europe, out of which Canada accounts for the majority of the revenue.

Share on Social Networks: